WO1999044630A1 - Preparations exemptes de proteines - Google Patents
Preparations exemptes de proteines Download PDFInfo
- Publication number
- WO1999044630A1 WO1999044630A1 PCT/JP1999/001080 JP9901080W WO9944630A1 WO 1999044630 A1 WO1999044630 A1 WO 1999044630A1 JP 9901080 W JP9901080 W JP 9901080W WO 9944630 A1 WO9944630 A1 WO 9944630A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stimulating factor
- granulocyte colony
- csf
- polyoxyethylene
- colony stimulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
Definitions
- the present invention relates to a preparation containing granulocyte colony-stimulating factor, particularly containing a granulocyte colony-stimulating factor which is stabilized by preventing loss or inactivation of an active ingredient due to adsorption or association on a container wall, polymerization, oxidation or the like. Formulation.
- G-CSF Granulocyte colony stimulating factor
- the applicant Since the applicant has purified high-purity human G-CSF by culturing a cell line collected from tumor cells of patients with oral floor cancer, it has succeeded in cloning the human G-CSF gene. Now, genetic engineering techniques have made it possible to produce large amounts of recombinant human G-CSF in animal cells. In addition, the applicant of the present application has succeeded in formulating the purified G-CSF, and supplies the product to the market as an anti-infection agent (Patent No. 211 6515).
- G-CSF is used in extremely small amounts, and usually contains 1 to 1000 ag (preferably 5 to 500 g) of G-CSF per adult per 1 to 7 doses / week I do.
- this G—C S F exhibits adsorptivity to the walls of, for example, ampoules for injection and injectors.
- G-CSF is unstable and susceptible to external factors, causing physical and chemical changes such as association, polymerization or oxidation due to temperature, humidity, oxygen, ultraviolet light, etc. Causes a large decrease in activity.
- An object of the present invention is to provide a preparation of G-CSF which reduces the complexity of the production process and is more stable for long-term storage. Disclosure of the invention
- the present inventors have found that even when a very small amount of a surfactant is added as a stabilizer, a stable G-CSF solution preparation can be obtained. And completed the present invention.
- the present invention comprises a granulocyte colony stimulating factor, and 0.001 to 1 part by weight of at least one pharmaceutically acceptable surfactant per 1 part by weight of granulocyte colony stimulating factor.
- a stable granulocyte colony stimulating factor-containing preparation having a particle size of 7 or less is provided.
- stabilization means that the G-CSF-containing solution preparation has a G-CSF residual ratio of 95% or more after storage for 6 months under storage conditions of 25 ° C, or storage conditions of 40. G-CSF retention after storage for 2 weeks at 75% or more.
- FIG. 1 is a graph showing the relationship between the pH and the residual G—CSF ratio after an accelerated test at 40 for 12 weeks.
- FIG. 2 is a graph showing the relationship between the ratio of 1 to 0 to 3 to sugar chain degradant formation after an accelerated test for 40 to 12 weeks.
- FIG. 3 is a graph showing the relationship between parts by weight of polysorbate 20 and parts by weight of polysorbate 20 per 1 part by weight of G-CSF 24 hours after filling.
- the G-CSF used in the solution preparation of the present invention can be any human G-CSF that is highly purified. Specifically, mammals, especially human G-CSF, And those having the same biological activity, including those of natural origin and those obtained by genetic recombination. G-CSF obtained by the genetic recombination method has the same amino acid sequence as natural G-CSF, or has one or more amino acid sequences deleted, substituted, or added, and has the above-mentioned biological activity.
- Including those having The G-CSF in the present invention may be produced by any method, such as those obtained by culturing a cell line of human tumor cells and extracting and purifying it by various methods, or Escherichia coli, Streptococcus pneumoniae, Chinese hamster ovary (CHO) cells, C127 cells, etc., are extracted and separated and purified by various methods. Most preferably, it is produced by a CHO cell using a genetic recombination method.
- the surfactant used to obtain the stable G-CSF-containing preparation of the present invention includes nonionic surfactants such as sorbitan fatty acid esters such as sorbitan monocaprylate, sorbitan monolaurate and sorbitan monopalmitate.
- nonionic surfactants such as sorbitan fatty acid esters such as sorbitan monocaprylate, sorbitan monolaurate and sorbitan monopalmitate.
- Glycerin fatty acid esters such as glycerin monocaprylate, glycerin monomitrate, glycerin monostearate; polyglycerin fatty acid esters such as decaglyceryl monostearate, decaglyceryl distearate, decaglyceryl monolinoleate; polyoxyethylene sorbitan Polyoxyethylenes such as monomonolaurate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monostearate, trioleate, polyoxyethylene sorbitan tristearate, etc.
- Sorbitan fatty acid ester such as polyoxyethylene sorbite tetrastearate and polyoxyethylene sorbite tetraoleate; polyoxyethylene glycerin fatty acid ester such as polyoxyethylene glyceryl monostearate; polyethylene glycol distearate Polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether; polyoxyethylene polyoxypropylene dalycol ether, polyoxyethylene polyoxypropylene propyl ether, and polyoxyethylene polypropylene propylene ester.
- Polyoxyethylene polyoxypropylene alkyl ethers such as tyl ether; Polyoxyethylene alkyl phenol ethers such as polyoxychelenonyl phenyl ether; polyoxyethylene hydrogenated castor oils such as polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil (polyoxyethylene hydrogen castor oil)
- a boroxyethylene beeswax derivative such as polyoxyethylene sorbit mire; a polyoxyethylene lanolin derivative such as polyoxyethylene lanolin; an HLB 6 to 6 of polyoxyethylene fatty acid amide such as polyoxyethylene stearamide.
- anionic surfactants for example, alkyl sulfates having an alkyl group having 10 to 18 carbon atoms, such as sodium cetyl sulfate, sodium lauryl sulfate, and sodium oleyl sulfate; polyoxyethylene sodium lauryl sulfate Etc., ethylene Polyoxyethylene alkyl ether sulfate having an average addition mole number of oxide of 2 to 4 and alkyl group of 10 to 18 carbon atoms; such as sodium lauryl sulfosuccinate having an alkyl group of 8 to 8 carbon atoms Typical examples include alkyl sulfosuccinate salts of 18; natural surfactants such as lecithin and glycerophospholipid; fingolipids such as sphingomyelin; and sucrose fatty acid esters of fatty acids having 12 to 18 carbon atoms. It can be mentioned as.
- One or more of these surfactants can be added to the solution preparation of the
- Preferred surfactants are polyoxyethylene sorbin fatty acid esters, particularly preferred are polysorbates 20, 21, 40, 60, 65, 80, 81, 85, most preferred Polysorbates 20 and 80.
- the amount of the surfactant to be added to the G-CSF-containing preparation of the present invention is generally 0.001 to 1 part by weight per 1 part by weight of G-CSF, preferably 1 part by weight of G-CSF. Part by weight, more preferably 0.1 to 1 part by weight, more preferably 0.2 to 1 part by weight of G—CSF, and more preferably 1 to 1 part by weight of G—CSF.
- the amount is 0.2 to 0.8 part by weight, most preferably 4 to 0.8 part by weight based on 1 part by weight of G-CSF.
- the amount of surfactant added is preferably 100 g.
- the addition amount of the surfactant is preferably 0.4 parts by weight or 0.8 parts by weight per 1 part by weight of G-CSF. Reducing evening protein such as albumin
- the surfactant was not added as a stabilizing agent, if the amount of the surfactant exceeded 1 part by weight based on 1 part by weight of G-CSF, the G-CSF residual ratio after long-term storage tended to decrease. . Even when the amount of the surfactant added is 1 part by weight or less with respect to 1 part by weight of G-CSF, the adsorption of G-CSF to the container can be sufficiently suppressed.
- Preferred G-CSF containing formulations of the present invention are substantially free of proteins as stabilizers.
- Some products currently on the market include proteins such as human serum albumin or purified gelatin as stabilizers to suppress chemical and physical changes in G-CSF.
- proteins such as human serum albumin or purified gelatin as stabilizers to suppress chemical and physical changes in G-CSF.
- a protein as a stabilizing agent has problems such as the necessity of a very complicated process for removing viral contamination.
- the G-CSF-containing preparation of the present invention has a pH of 7 or less, preferably has a pH of 5 to 7, more preferably has a pH of 6 to 6.8, and most preferably has a pH of 6. 2 to 6.8.
- the G—CSF residual ratio after the accelerated test for 40 to 12 weeks is stable when the pH is 7 or less.
- the pH is preferably about 7.0 or less.
- the pH is preferably about 5 or more.
- the pH is close to neutral with little irritation to the human body. When these are combined, it is most preferable that the pH be 6.2 to 6.8.
- the G-CSF-containing preparation of the present invention contains a diluent, a solubilizing agent, a tonicity agent, an excipient, a pH adjuster, a soothing agent, a buffer, a sulfur-containing reducing agent, an antioxidant, and the like.
- a diluent such as polyethylene glycol; dextran, mannitol, sorbitol, inositol, glucose, fructose, lactose, xylose, mannose, maltose, cyclose, and raffinose can be used. it can.
- sulfur-containing reducing agent examples include N-acetyl cysteine, N-acetyl homocystine, choctolic acid, thiodiglycol, thioethanolamine, thioglycerol, thiosorbitol, thioglycolic acid and salts thereof, sodium thiosulfate, and glue.
- antioxidants include erythorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, ⁇ -tocopherol, tocopherol acetate, L-ascorbic acid and salts thereof, L-ascorbic acid palmitate, L-ascorbic acid stearate, Chelating agents such as sodium bisulfite, sodium sulfite, triamyl gallate, propyl gallate or disodium ethylenediaminetetraacetate (EDTA), sodium pyrophosphate, sodium metaphosphate and the like.
- EDTA disodium ethylenediaminetetraacetate
- Amino acids such as glycine, cystine, threonine, cystine, tryptophan, methionine, lysine, hydroxylysine, histidine and arginine may be added as excipients.
- inorganic salts such as sodium chloride, potassium chloride, calcium chloride, sodium phosphate, potassium phosphate, and sodium hydrogen carbonate; solutions such as organic salts such as sodium citrate, potassium citrate, and sodium acetate; It may contain components normally added to the preparation.
- the amount of G-CSF contained in the solution preparation of the present invention can be determined according to the type of the disease to be treated, the severity of the disease, the age of the patient, etc., but generally 1 to 100 / X gm L, preferably 10 to 800 zg Zm L, more preferably 50 to 500 g Zm L.
- the solution preparation of the present invention can be prepared by dissolving these components in an aqueous buffer known in the field of solution preparations such as phosphate and Z or citrate buffers.
- the phosphate buffer is preferably a sodium monohydrogen phosphate monosodium dihydrogen phosphate system
- the citrate buffer is preferably a sodium citrate buffer.
- the stabilized G-CSF-containing preparation of the present invention is usually administered by a parenteral administration route, for example, an injection (subcutaneous injection, intravenous injection or intramuscular injection), transdermal, transmucosal, nasal, pulmonary, and the like.
- a parenteral administration route for example, an injection (subcutaneous injection, intravenous injection or intramuscular injection), transdermal, transmucosal, nasal, pulmonary, and the like.
- an injection subcutaneous injection, intravenous injection or intramuscular injection
- transdermal transmucosal
- nasal, pulmonary and the like.
- oral administration is also possible.
- the G-CSF-containing formulation of the present invention is usually housed in a hermetically sealed, sterilized plastic or glass container.
- the containers can be supplied in fixed dose form, such as in ampules, vials or disposable syringes, or in large dose forms, such as injection bags or bottles.
- the G-CSF-containing preparation of the present invention has an extremely good G-CSF residue even after an accelerated test at 40 for 12 weeks or a storage at 25 ° C for 6 months. Indicates the rate.
- G-CSF has one or two sialic acids at the sugar chain terminus, but sialic acid may decompose during long-term storage.
- the G-CSF-containing preparation of the present invention was shown to keep the degradation product generation ratio low even after an accelerated test at 40 to 2 weeks.
- the G-CSF-containing preparation of the present invention can sufficiently suppress the adsorption to the container, and regardless of the shape of the container such as a vial-filled preparation and a syringe-filled preparation, after the accelerated test for 40 to 12 weeks, And 25 show very good G-CSF persistence after storage for 16 months.
- Each preparation is aseptically prepared, filtered, and then aseptically placed in vials. Each was filled and sealed to produce a G-CSF solution preparation.
- the G—CSF content in the vial was measured according to Method 1 below.
- the content of G—CSF sugar chain decomposed product in the vial was measured based on the following method 2.
- G-CSF glycosylated product (all sialic acids present at the sugar chain ends were degraded) and G-CSF (unmodified product) were detected by anion-exchange high-performance liquid chromatography. . That is, using an anion exchange column (TSKgelDEAE), eluting with 20 mM Tris-HC1 buffer (pH 7.4) as a mobile phase and NaC1 gradient (0-50 OmM), and separating at a wavelength of 215 nm. Optically detected. Using the measured values of the G-CSF glycosylated product and the G-CSF unchanged product measured by this method, the G-CSF glycosylated product formation ratio (% ) was calculated.
- TSKgelDEAE anion exchange column
- each of the polysorbates After adding 250 mg of G-CSF and 5.844 g of sodium chloride, further add each of the polysorbates to a concentration of 20 as shown in Table 2 below, and adjust the pH to 6 with sodium phosphate buffer. Adjusted to 5 so that the total volume was 1L.
- the adsorption inhibition rate (%) 24 hours after filling was calculated based on the following equation.
- the G-CSF content in the vial or syringe was measured according to Method 1, and the G-CSF remaining rate after acceleration at 40 to 2 weeks, and the G—CSF remaining after storage at 25 ° C for 6 months The rate was calculated by the formula described in Method 1.
- the G-CSF preparation of the present invention has a residual rate of 75% or more after acceleration for 12 weeks at 40 and a storage time of 16 months at 25 in both the vial-filled preparation and the syringe-filled preparation.
- the residual rate after that was 95% or more, indicating excellent stability.
- the G-SCF-containing preparation of the present invention contains a very small amount of a surfactant of 1 part by weight or less per 1 part by weight of G-CSF, the temperature and humidity of G-CSF present in a trace amount in the preparation can be improved. Can effectively solve problems related to loss of active ingredients, loss of activity, etc. resulting from association, polymerization, or oxidation or adsorption to container walls based on external factors such as oxygen, ultraviolet rays, etc. . Therefore, the present invention is to provide a solution preparation which reduces the complexity and cost in the production process and is stable even for long-term storage.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99937832A EP1060746A4 (en) | 1998-03-06 | 1999-03-05 | PROTEIN-FREE PREPARATIONS |
AU32751/99A AU749815B2 (en) | 1998-03-06 | 1999-03-05 | Protein-free preparations |
JP2000534231A JP3895109B2 (ja) | 1998-03-06 | 1999-03-05 | 蛋白非添加製剤 |
US09/622,487 US6776983B1 (en) | 1998-03-06 | 1999-03-05 | Protein free formulations |
HK01107097A HK1036224A1 (en) | 1998-03-06 | 2001-10-09 | Protein-free preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/54799 | 1998-03-06 | ||
JP5479998 | 1998-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999044630A1 true WO1999044630A1 (fr) | 1999-09-10 |
Family
ID=12980811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/001080 WO1999044630A1 (fr) | 1998-03-06 | 1999-03-05 | Preparations exemptes de proteines |
Country Status (9)
Country | Link |
---|---|
US (1) | US6776983B1 (ja) |
EP (2) | EP1952820A3 (ja) |
JP (1) | JP3895109B2 (ja) |
KR (1) | KR100389726B1 (ja) |
CN (1) | CN1264569C (ja) |
AU (1) | AU749815B2 (ja) |
HK (1) | HK1036224A1 (ja) |
TW (1) | TW589188B (ja) |
WO (1) | WO1999044630A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1329224A1 (en) * | 2000-09-01 | 2003-07-23 | Chugai Seiyaku Kabushiki Kaisha | Solution formulations having long-term stability |
JP2003533466A (ja) * | 2000-05-18 | 2003-11-11 | ツェンタリス アクチエンゲゼルシャフト | ペプチドの薬剤適用形、その製造法及び使用 |
JP2006346494A (ja) * | 1999-02-22 | 2006-12-28 | Chugai Pharmaceut Co Ltd | プレフィルドシリンジタンパク質溶液製剤 |
US20090264629A1 (en) * | 2003-02-28 | 2009-10-22 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
JP2011025068A (ja) * | 1999-02-22 | 2011-02-10 | Chugai Pharmaceut Co Ltd | プレフィルドシリンジタンパク質溶液製剤 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011753A1 (fr) * | 2000-08-04 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Preparations proteiniques a injecter |
EP1682184B1 (en) * | 2003-11-04 | 2013-10-16 | LEK Pharmaceuticals d.d. | Stable pharmaceutical composition comprising granulocyte-colony stimulating factor |
DE202006020194U1 (de) * | 2006-03-01 | 2007-12-06 | Bioceuticals Arzneimittel Ag | G-CSF-Flüssigformulierung |
MX2010002348A (es) | 2007-08-27 | 2010-07-30 | Biogenerix Ag | Formulacion liquida de g-csf. |
US8323634B2 (en) * | 2009-01-16 | 2012-12-04 | Teva Pharmaceutical Industries Ltd. | Stable formulations of highly concentrated recombinant human albumin-human granulocyte colony stimulating factor |
RU2519031C1 (ru) | 2010-01-19 | 2014-06-10 | Ханми Сайенс Ко., Лтд. | Жидкие препаративные формы для длительно действующего конъюгата g-csf |
ES2968043T3 (es) | 2011-06-10 | 2024-05-06 | Hanmi Science Co Ltd | Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que comprende la misma |
KR101577734B1 (ko) | 2011-06-17 | 2015-12-29 | 한미사이언스 주식회사 | 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도 |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
SG11201503370WA (en) | 2012-11-06 | 2015-05-28 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63146826A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
JPH06510031A (ja) * | 1991-08-15 | 1994-11-10 | ロシュ ダイアグノスティックス ゲーエムベーハー | ヒトタンパク質を含有する注入用又は注射用医薬製剤の製造方法 |
JPH08504784A (ja) * | 1992-12-18 | 1996-05-21 | ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング | G−csfの安定凍結乾燥薬理製剤 |
JPH08505610A (ja) * | 1992-12-18 | 1996-06-18 | ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 貯蔵安定性なg−csfの水性薬理製剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR871067B (en) * | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
CA1339071C (en) * | 1988-08-24 | 1997-07-29 | Koichiro Tsuji | Thrombus control agent |
JPH02116515A (ja) | 1988-10-26 | 1990-05-01 | Matsushita Electric Works Ltd | 無機質建材の製造方法 |
JP3022915B2 (ja) * | 1990-07-17 | 2000-03-21 | 市郎 東 | 癌転移抑制剤 |
JP3655645B2 (ja) * | 1992-02-28 | 2005-06-02 | 中外製薬株式会社 | 経粘膜投与剤 |
-
1999
- 1999-03-05 AU AU32751/99A patent/AU749815B2/en not_active Ceased
- 1999-03-05 US US09/622,487 patent/US6776983B1/en not_active Expired - Lifetime
- 1999-03-05 EP EP08005357A patent/EP1952820A3/en not_active Withdrawn
- 1999-03-05 WO PCT/JP1999/001080 patent/WO1999044630A1/ja not_active Application Discontinuation
- 1999-03-05 JP JP2000534231A patent/JP3895109B2/ja not_active Expired - Fee Related
- 1999-03-05 EP EP99937832A patent/EP1060746A4/en not_active Withdrawn
- 1999-03-05 CN CNB998037354A patent/CN1264569C/zh not_active Expired - Fee Related
- 1999-03-05 KR KR10-2000-7009765A patent/KR100389726B1/ko active IP Right Grant
- 1999-03-06 TW TW088103477A patent/TW589188B/zh not_active IP Right Cessation
-
2001
- 2001-10-09 HK HK01107097A patent/HK1036224A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63146826A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
JPH06510031A (ja) * | 1991-08-15 | 1994-11-10 | ロシュ ダイアグノスティックス ゲーエムベーハー | ヒトタンパク質を含有する注入用又は注射用医薬製剤の製造方法 |
JPH08504784A (ja) * | 1992-12-18 | 1996-05-21 | ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング | G−csfの安定凍結乾燥薬理製剤 |
JPH08505610A (ja) * | 1992-12-18 | 1996-06-18 | ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 貯蔵安定性なg−csfの水性薬理製剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1060746A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006346494A (ja) * | 1999-02-22 | 2006-12-28 | Chugai Pharmaceut Co Ltd | プレフィルドシリンジタンパク質溶液製剤 |
JP2011025068A (ja) * | 1999-02-22 | 2011-02-10 | Chugai Pharmaceut Co Ltd | プレフィルドシリンジタンパク質溶液製剤 |
JP2013248527A (ja) * | 1999-02-22 | 2013-12-12 | Chugai Pharmaceut Co Ltd | プレフィルドシリンジタンパク質溶液製剤 |
JP2003533466A (ja) * | 2000-05-18 | 2003-11-11 | ツェンタリス アクチエンゲゼルシャフト | ペプチドの薬剤適用形、その製造法及び使用 |
JP2011213733A (ja) * | 2000-05-18 | 2011-10-27 | Aeterna Zentaris Gmbh | ペプチドの薬剤適用形、その製造法及び使用 |
EP1329224A1 (en) * | 2000-09-01 | 2003-07-23 | Chugai Seiyaku Kabushiki Kaisha | Solution formulations having long-term stability |
EP1329224A4 (en) * | 2000-09-01 | 2004-04-14 | Chugai Pharmaceutical Co Ltd | PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME |
US7998929B2 (en) | 2000-09-01 | 2011-08-16 | Chugai Seikyaku Kabushiki Kaisha | Solution preparations stabilized over long time |
US20090264629A1 (en) * | 2003-02-28 | 2009-10-22 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
US9968677B2 (en) * | 2003-02-28 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
Also Published As
Publication number | Publication date |
---|---|
EP1060746A4 (en) | 2002-06-19 |
EP1060746A1 (en) | 2000-12-20 |
CN1264569C (zh) | 2006-07-19 |
US6776983B1 (en) | 2004-08-17 |
CN1292705A (zh) | 2001-04-25 |
EP1952820A2 (en) | 2008-08-06 |
JP3895109B2 (ja) | 2007-03-22 |
EP1952820A3 (en) | 2012-06-20 |
KR20010041576A (ko) | 2001-05-25 |
HK1036224A1 (en) | 2001-12-28 |
KR100389726B1 (ko) | 2003-06-27 |
AU749815B2 (en) | 2002-07-04 |
AU3275199A (en) | 1999-09-20 |
TW589188B (en) | 2004-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6076226B2 (ja) | タンパク質溶液製剤およびその安定化方法 | |
JP4607336B2 (ja) | 長期安定化製剤 | |
JP4683810B2 (ja) | 長期安定化製剤 | |
WO1999044630A1 (fr) | Preparations exemptes de proteines | |
EP0909564B1 (en) | Erythropoietin solution preparation stabilized with amino acids | |
JP5490972B2 (ja) | タンパク質注射製剤 | |
JP2007204498A (ja) | 長期安定化製剤 | |
WO2002017957A1 (fr) | Preparations de solutions stabilisees sur une longue periode de temps | |
JP5271481B2 (ja) | タンパク質溶液製剤およびその安定化方法 | |
JP2577742B2 (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 | |
JP4454571B2 (ja) | 蛋白非添加製剤 | |
EP1166773B1 (en) | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof | |
WO2023233277A1 (en) | Lyophilized pharmaceutical compositions of copper histidinate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99803735.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 32751/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999937832 Country of ref document: EP Ref document number: 09622487 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007009765 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999937832 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007009765 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 32751/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007009765 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999937832 Country of ref document: EP |